Literature DB >> 12045498

Severe and Norwegian scabies are strongly associated with retroviral (HIV-1/HTLV-1) infection in Bahia, Brazil.

Carlos Brites1, Mônica Weyll, Célia Pedroso, Roberto Badaró.   

Abstract

Severe scabies has been associated with HTLV infection. To evaluate the impact of HTLV-I/HIV-1 co-infection on the clinical presentation of scabies, we reviewed 91 cases of scabies in Bahia, Brazil, during a 3 year period. Infections by HIV-1 (50%), HTLV-I (32%), and both (20%) were highly prevalent. Crusted or severe scabies were strongly associated with HTLV-I and, to a lesser degree, with HIV-1 infection. Co-infected patients had a higher risk of death (P = 0.01). Severe forms of scabies were highly predictive of double retroviral infection.

Entities:  

Mesh:

Year:  2002        PMID: 12045498     DOI: 10.1097/00002030-200206140-00015

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  21 in total

Review 1.  Interference with immune function by HTLV-1.

Authors:  P K C Goon; C R M Bangham
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

2.  Neonatal Norwegian scabies: three cooperating causes.

Authors:  Giulio Gualdi; Laura Bigi; Giovanna Galdo; Giovanni Pellacani
Journal:  J Dermatol Case Rep       Date:  2009-08-24

Review 3.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  A scabies outbreak in a diabetic and collagen disease ward: Management and prevention.

Authors:  Kenta Furuya; Hitoshi Nakajima; Yousuke Sasaki; Akira Ishiko; Yoshihisa Urita
Journal:  Exp Ther Med       Date:  2016-10-27       Impact factor: 2.447

5.  Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection.

Authors:  Anselmo Souza; Natália Carvalho; Yuri Neves; Silvane Braga Santos; Maria de Lourdes Bastos; Sérgio Arruda; Eduardo Martins Netto; Marshall J Glesby; Edgar Carvalho
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-26       Impact factor: 2.205

6.  Evaluation of the microbicidal activity and cytokines/chemokines profile released by neutrophils from HTLV-1-infected individuals.

Authors:  Caroline A Bezerra; Thiago M Cardoso; Angela Giudice; Aurélia F Porto; Silvane B Santos; Edgar M Carvalho; Olívia Bacellar
Journal:  Scand J Immunol       Date:  2011-09       Impact factor: 3.487

7.  Impairment of the humoral and CD4(+) T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid.

Authors:  Anselmo Souza; Silvane Santos; Lucas P Carvalho; Maria Fernanda R Grassi; Edgar M Carvalho
Journal:  Hum Immunol       Date:  2016-06-06       Impact factor: 2.850

8.  Prevalence of human T-cell lymphotropic virus type 1 infection in hospitalized patients with tuberculosis.

Authors:  M de Lourdes Bastos; B Osterbauer; D L Mesquita; C A Carrera; M J Albuquerque; L Silva; D N Pereira; L Riley; E M Carvalho
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

9.  Development and validation of a multiplex real-time PCR assay for simultaneous genotyping and human T-lymphotropic virus type 1, 2, and 3 proviral load determination.

Authors:  Britta Moens; Giovanni López; Vanessa Adaui; Elsa González; Lien Kerremans; Daniel Clark; Kristien Verdonck; Eduardo Gotuzzo; Guido Vanham; Olivier Cassar; Antoine Gessain; Anne-Mieke Vandamme; Sonia Van Dooren
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

10.  Influence of HTLV-1 on the clinical, microbiologic and immunologic presentation of tuberculosis.

Authors:  Maria de Lourdes Bastos; Silvane B Santos; Anselmo Souza; Brooke Finkmoore; Ohana Bispo; Tasso Barreto; Ingrid Cardoso; Iana Bispo; Flávia Bastos; Daniele Pereira; Lee Riley; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2012-08-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.